In a patient with acute leukemia, immunophenotype pattern is CD 19+ve, CD 10+ve, CD33+ve, CD 13+ve. He may probably have –
**Core Concept**
The question is testing the ability to identify a specific type of leukemia based on immunophenotypic markers. Immunophenotyping is a technique used to identify specific cell surface proteins or antigens on cancer cells, which can help diagnose and classify different types of leukemia. The markers mentioned in the question, such as CD19, CD10, CD33, and CD13, are commonly used to identify various subtypes of acute leukemia.
**Why the Correct Answer is Right**
The combination of CD19+ve, CD10+ve, CD33+ve, and CD13+ve immunophenotypic markers is characteristic of Acute Lymphoblastic Leukemia (ALL), specifically the precursor B-cell ALL (BCP-ALL) subtype. CD19 is a B-cell specific marker, while CD10 is often expressed in precursor B-cells. CD33 and CD13 are myeloid markers, but in the context of BCP-ALL, their co-expression with CD19 and CD10 suggests a complex immunophenotypic profile. This pattern is not typical of Acute Myeloid Leukemia (AML), which would more commonly express CD33 and CD13 without CD19 and CD10.
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is not provided, so we'll skip it.
* **Option B:** This option is not provided, so we'll skip it.
* **Option C:** This option is not provided, so we'll skip it.
* **Option D:** This option is not provided, so we'll skip it.
**Clinical Pearl / High-Yield Fact**
It's essential to remember that the immunophenotypic profile of leukemia can vary widely, and not all cases fit neatly into a specific category. A combination of clinical presentation, laboratory findings, and immunophenotyping is often required to establish a definitive diagnosis. Additionally, the expression of certain markers can change over time, so repeated testing may be necessary to confirm the diagnosis.
**Correct Answer:** D.